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The role of the divalent cation in the structure of the I domain
from the CD11a/CD18 integrin
Aidong Qu and Daniel J Leahy*
Background:  The integrin family of cell-surface receptors mediates a wide
variety of cell–cell and cell–extracellular matrix interactions. Integrin–ligand
interactions are invariably dependent on the presence of divalent cations, and a
subset of integrins contain a ~200 amino acid inserted (I) domain that is
important for ligand binding activity and contains a single divalent cation binding
site. Many integrins are believed to respond to stimuli by undergoing a
conformational change that increases their affinity for ligand, and there is a clear
difference between two crystal structures of the CD11b I domain with different
divalent cations (magnesium and manganese) bound. In addition to the different
bound cation, a ‘ligand mimetic’ crystal lattice interaction in the CD11b I domain
structure with bound magnesium has led to the interpretation that the different
CD11b I domain structures represent different affinity states of I domains. The
influence of the bound cation on I domain structure and function remains
incompletely understood, however. The crystal structure of the CD11a I domain
bound to manganese is known. We therefore set out to determine whether this
structure changes when the metal ion is altered or removed.
Results: We report here the crystal structures of the CD11a I domain determined
in the absence of bound metal ion and with bound magnesium ion. No major
structural rearrangements are observed in the metal-binding site of the CD11a I
domain in the absence or presence of bound manganese ion. The structures of the
CD11a I domain with magnesium or manganese bound are extremely similar.
Conclusions: The conformation of the CD11a I domain is not altered by
changes in metal ion binding. The cation-dependence of ligand binding thus
indicates that the metal ion is either involved in direct interaction with ligand or
required to promote a favorable quaternary arrangement of the integrin.
Introduction
Members of the integrin family of cell-surface receptors
are typically involved in some aspect of cell adhesion
through interactions with components of the extracellular
matrix or other cell-surface receptors [1]. Integrins are non-
covalently associated heterodimers consisting of a 120–180
kDa a chain and a 90–120 kDa b chain. Both a and b
chains are single-pass transmembrane proteins with large
extracellular components and variable but generally small
cytoplasmic regions. Over 20 different integrins have been
identified with many integrins sharing common subunits.
The CD11a/CD18 (LFA-1, aLb2) integrin is expressed on
all leukocytes and mediates adhesion to a variety of cell
types that express one or more of the CD11a/CD18
ligands, the intercellular adhesion molecules (ICAMs),
ICAM-1, ICAM-2, or ICAM-3. The processes mediated 
by CD11a/CD18 interactions include adhesion to the
endothelium and extravasation at sites of inflammation
and adherence of activated T cells to target cells [2].
Integrins have been shown to transmit signals in both
directions across the cell membrane [1]. Interactions of an
integrin with ligand have been shown to alter the behavior
or properties of the integrin-bearing cell, and the affinity
of many integrins for ligand is increased following appro-
priate cellular stimuli. This increase in affinity is believed
to be accompanied by conformational changes in the inte-
grin [1,3]. Interactions of integrins with ligands are depen-
dent on the presence of divalent cations, with Mg2+ being
the likely physiological cation in most circumstances.
Several integrins have a higher affinity for Mn2+, however,
and Mn2+ is capable of inducing the high-affinity state of
these integrins in the absence of other stimuli [4–6].
A subset of integrin a chains, including CD11a, contain an
inserted or ‘I’ domain of ~200 amino acids. I domains
belong to a family of homologous domains of which von
Willebrand factor ‘A’ domains are the prototype [7,8]. In
each of these integrins the I domain has been shown to
provide a large component of ligand-binding activity
[6,9–14]. The crystal structures of the CD11b I domain
with bound magnesium [15] and the CD11a and CD11b I
domains with bound manganese [16,17] have recently
been determined and reveal these domains to possess a
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flavodoxin-like dinucleotide-binding fold [18,19]. Instead
of a dinucleotide cofactor, however, the I domains bind a
divalent cation through a conserved amino acid sequence
motif Asp-X-Ser-X-Ser (DXSXS). The presence of this
sequence motif in integrin b chains together with a con-
served pattern of hydrophobicity between I domains and
this region in integrin b chains has led to speculation that
integrin b chains may also contain an I domain-like struc-
ture [15]. Mutations of the divalent cation binding motif
in both I domains and integrin b chains impair ligand
binding [6,20–22].
The mechanisms by which integrins increase their affinity
for ligand and the role that divalent cations play in both
activation and ligand binding remain incompletely under-
stood. Two nonexclusive mechanisms have been proposed
to explain the metal dependence of integrin–ligand inter-
actions. The first mechanism proposes that the metal may
be required to stabilize an active tertiary or quaternary con-
formation of the integrin; the second that the integrin-
bound metal ion may participate directly in interactions
with ligand, possibly through interactions between the
metal ion and an acidic residue in the ligand. The frequent
occurrence of acidic amino acids in the ligand- binding
sites recognized by integrins [1] and a direct interaction
between a glutamic acid side chain from an adjacent mole-
cule in the crystal lattice and a bound magnesium ion in
the CD11b I domain crystal structure [15] have been cited
as indications that the metal ion participates directly in
ligand binding. A series of mutations in the CD11a I
domain that abolish ligand binding also map in the vicinity
of the metal-binding surface [22]. Other studies, however,
have suggested that cation and ligand binding are separa-
ble properties of integrins [21,23], and a region of the
CD11a I domain that is critical for ICAM-3 binding maps
to a region diametrically opposite the metal-binding
surface [24].
A molecular understanding of the differing effects of spe-
cific cations on ligand binding by integrins also remains
elusive. The nature of the metal coordination differs
between the structure of the CD11b I domain with bound
magnesium, and the structures of the CD11a and CD11b I
domains with bound manganese, despite conservation of
the amino acids that interact with the metal ion and octa-
hedral coordination geometry. Differences in the metal-
binding site structure of the CD11b I domain with bound
magnesium or bound manganese appear correlated with
additional structural changes, particularly differences in an
a helix, a7. These differences have been proposed to
reflect high- and low-affinity states of the I domain [17].
The amino acid sequence similarity (36% identity
between CD11a and CD11b with 33% identity in the I
domains [7]) and the consequent structural similarity, the
conserved metal-binding motif, a common b subunit, and
similar activation behavior suggest that the structural 
features of activation will be similar for the CD11a/CD18
and CD11b/CD18 integrins.
To evaluate the effects of metal binding on I domain struc-
ture we have determined and report here the crystal struc-
ture of the CD11a I domain in the absence of bound metal
ion. To evaluate the influence of the specific metal ion
bound versus the effects of a ‘ligand mimetic’ crystal lattice
interaction on I domain structure, we have also determined
and report here the crystal structure of the CD11a I domain
with bound magnesium ion. These structures are compared
with the previously determined structure of the CD11a I
domain with bound manganese ion.
Results
Determination of the metal-free structure of the CD11a I
domain
The crystal structure of a metal-free form of the CD11a I
domain (CD11a-I(EDTA)) was solved by the multi-
wavelength anomalous diffraction (MAD) method.
MAD-phased electron-density maps allowed confident
placement of all residues in CD11a-I(EDTA) except for
the four N-terminal residues (Cys125–Gly128) and 15 C-
terminal residues (Lys297–Gly311). Sufficient electron
density was present for residues 297 to 308 to determine
that these residues form a helical structure and to trace
the general course of this helix. Inclusion of these
residues in the atomic model resulted in a 0.4% decrease
in the free R value [25]. However, atomic positions for
these residues are poorly defined, with an average B
factor of 63 Å2 for residues 297–308. Inspection of both
experimentally-phased electron-density maps and differ-
ence maps calculated during refinement confirmed the
absence of a divalent cation in the conserved metal-
binding site of CD11-I(EDTA) (see Fig. 1a). Data collec-
tion results, refinement statistics, and stereochemical
parameters for the CD11a-I(EDTA) structure are shown
in Tables 1–3.
Determination of the manganese- and magnesium-bound
structures of the CD11a I domain
Crystals of the CD11a I domain refolded in the presence
of Mg2+, CD11a-I(Mg), remained relatively small and dif-
fraction data beyond 2.8–3.0 Å Bragg spacings could not be
accurately measured. Virtually isomorphous crystals of the
CD11a I domain with bound manganese, CD11a-I(Mn),
were obtained, however, that diffracted to at least 2.0 Å
Bragg spacings. The structure of CD11a-I(Mn) in this new
space group P21212 was solved by molecular replacement
using the structure of this domain previously determined
in the space group C2 [16] as a search model. The asym-
metric unit of the P21212 crystal form contained two mole-
cules of the CD11a I domain arranged identically to the
two molecules in the asymmetric unit of the C2 crystal
form, and the molecular replacement solution refined
easily to low R factor. The common arrangement of the
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independent molecules in the asymmetric units of both
the C2 and P21212 crystal forms involves an interaction of
the C termini of the adjacent molecules that appears to
influence the disposition of the a7 helix relative to the rest
of the molecule. Gel filtration chromatography reveals
that, in the presence of Mn2+, the CD11a I domain exists
in an equilibrium between monomer and dimer in solution
(data not shown). The involvement of the artificially-trun-
cated C terminus of the I domain in the dimer interaction
indicates that this interaction is unlikely to be physiologi-
cally relevant. Refinement statistics and stereochemical
parameters for the P21212 CD11a-I(Mn) structure are
shown in Table 4.
Simulated annealing omit maps [26] confirmed that the
manganese coordination is identical in the C2 and P21212
crystal forms. As shown in Figure 1b, the manganese ion is
directly coordinated by Ser139, Ser141, and Asp239 while
Thr206 makes a hydrogen bond to one of two manganese-
bound waters. The coordination geometry is octahedral,
and an apparent chloride ion is the sixth metal ligand. A
chloride ion is presumed for several reasons; the character-
istic interatomic distance (~2.5 Å); the observed intensity
of the scatterer at this site; the resulting neutrality of the
manganese coordination sphere if this site is occupied by a
monovalent anion; and chloride is the only monovalent
anion added to the crystallization mixture. The root mean
square (rms) deviations in Ca positions between the inde-
pendent CD11a I domains in the C2 and P21212 crystal
forms are 0.23–0.26 Å; these values are comparable to the
differences found between the independent molecules
within the asymmetric unit of either crystal form.
The virtual isomorphism of the P21212 crystal forms of the
CD11a I domain refolded in either Mn2+ or Mg2+ allowed
the determination of the Mg2+ structure by rigid-body
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Figure 1
Simulated annealing omit maps [26] of the CD11a metal-binding site
in the presence and absence of divalent cation contoured at 1.2s: (a)
CD11a-I(EDTA) calculated at 2.0 Å, (b) CD11a-I(Mn) calculated at 2.0
Å, and (c) CD11a-I(Mg) calculated at 3.0 Å. The maps are displayed
with the final model positions of residues Asp137–Ser141, Thr206,
Asp239, and any water molecules or metal ions in the metal-binding
site. Water molecules are shown as red spheres, manganese and
magnesium ions are in purple and green, respectively. In (b) an
additional water molecule bound to the manganese ion has been
clipped from view for clarity. In all structures atoms within an 8 Å
sphere around the metal ion were omitted from refinement and map
calculations. (Figure made with the program O [40].)
Table 1
Data collection statistics for CD11a-I(EDTA).
Data collection statistics (30.0 to 2.2 Å)
Wavelength Number of reflections Redundancy Completeness* Signal Rsym*
(Å) (N) (%) (<I/σI>) (%)
0.9879 8476 9.7 97.0 19.2 11.1
0.9793 8526 10.2 97.6 19.1 11.7
0.9791 8513 9.8 97.4 19.0 11.4
0.9686 8544 10.0 98.0 18.8 11.9
*Rsym and completeness values were calculated considering Bijvoets equivalent. Rsym=100 × ΣhΣi |Ii(h)–<|(h)>| /ΣhΣi|i(h).
refinement of the Mn2+-containing structure. To avoid
potential model bias from the metal-binding region of the
Mn2+ structure, a simulated annealing refinement of the
Mn2+ structure was carried out prior to the rigid-body
refinement. In this simulated-annealing, refinement atoms
within an 8 Å sphere of the manganese ion in one of the
molecules in the asymmetric unit were omitted from the
refinement calculations. An independent simulated anneal-
ing refinement was carried out in which a similar sphere
around the manganese ion bound to the other I domain in
the crystallographic asymmetric unit was omitted from
refinement calculations. Rigid-body refinement of these
models with the CD11a-I(Mg) diffraction data resulted in
an R factor of 0.279 with an R free of 0.269 for all data
10–3.0 Å. Inspection of (2Fo–Fc)eifcalc difference maps led
to the repositioning of nine amino acid side chains in the
CD11a-I(Mg) model which resulted in an R factor of 0.279
and an R free of 0.264 without refinement. All attempts to
further refine the rigid-body solutions, while significantly
reducing the R factor, resulted in increases in R free, and
no further refinement was thus performed. Figure 1c shows
a simulated annealing omit map from which an 8 Å sphere
around the magnesium ion has been omitted from the map
calculation [26]. While the lower resolution of the Mg2+
structure does not permit evaluation of the precise detail of
the solvent molecules involved in the magnesium coordina-
tion, it is clear that Ser139, Ser141, and Asp239 directly
coordinate the magnesium ion while Thr206 does not. A
similar result was obtained when the region surrounding
the magnesium ion in the other molecule in the asymmetric
unit was omitted from the map calculation.
Comparison of CD11a-I(EDTA) and CD11a-I(Mn) structures
With the exception of a large shift in the position of the C
terminus of the a7 helix, the structure of CD11a-I(EDTA)
is very similar to the structure of CD11a-I(Mn) [16]. Owing
to the similarity of the CD11a-I(Mn) structures deter-
mined in different crystal forms (packing of the common
dimer in the asymmetric unit is very similar in the C2 and
P21212 crystal forms), one of the molecules in the asym-
metric unit of the C2 crystal form was used as a representa-
tive structure for comparisons. All I domain structures,
including those reported here, consist of a flavodoxin-like
dinucleotide-binding fold [18,19] with a core parallel b
sheet surrounded by a helices. Figure 2a shows a ribbon
diagram of the CD11a-I(EDTA) structure, and Figure 2b
shows a stereo view of a superposition of the Ca backbones
of CD11a-I(EDTA) and CD11a-I(Mn). Figure 3 shows the
distance between Ca atoms at each amino acid position
following superposition of the CD11a-I(EDTA) and
CD11a-I(Mn) structures. Distances between Ca atoms of
greater than 1.0 Å are observed in four places in the
CD11a-I structures: three loop regions (b1–a1, a4–b3 and
b4–a6) and the C terminus including a portion of the a7
helix. With the exception of the a4–b3 connection, each of
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Table 2
MAD structure factor ratios and anomalous scattering factors for CD11a-I(EDTA).
Wavelength (Å) Anomalous scattering factors
Wavelength (Å) 0.9879 0.9793 0.9792 0.9686 f′ f′′
(e) (e)
0.9879 0.047 0.073 0.066 0.070 -4.28 0.51
0.9793 0.065 0.053 0.078 -9.73 3.87
0.9791 0.076 0.071 -7.92 5.36
0.9686 0.063 -3.61 4.00
MAD structure factor ratios calculated using (rms[∆|F|])/(rms[|F|]) where
∆F is the Bijvoet difference at one wavelength (diagonal elements) or
the dispersive difference between two wavelengths (off diagonal
elements). Centric data were merged to a single value and are thus not
shown. The Bijvoet difference at the 0.9870 Å wavelength may be
taken instead as an upper limit of the noise of the anomalous signals.
Also shown are the anomalous components of the Se scattering
factors as a function of wavelength as determined by MADLSQ [35].
Table 3
Final refinement and stereochemical statistics 
for CD11a-I(EDTA).
R value
(F>2s, 6.0–2.0 Å) 0.184 
(all F, 6.0–2.0 Å) 0.198
Rfree
(F>2s, 6.0–2.0 Å) 0.243 
(all F, 6.0–2.0 Å) 0.252
Average B (Å2)
for protein  21.92
for solvent 29.24
Rms deviations
bonds (Å) 0.009
angles (°) 1.90
B values (Å2)
bonds/angles of main chains 0.98/1.10
bonds/angles of side chains 1.74/1.82 
A subset of the data (5%) was excluded from refinement and used for
the free R value calculation [25]. All data for which |F|>2s were used
in the refinement. R value=S||Fo|–|Fc||/S|Fo|.
these regions is involved in a crystal lattice contact in
either one or both of the CD11a-I(EDTA) and CD11a-
I(Mn) structures that may be in part responsible for the
slight shifts in these loops [27,28]. The shift in the relative
position of the a4–b3 loop in the CD11a-I(EDTA) and
CD11a-I(Mn) structures is accompanied by the presence
of an intramolecular hydrogen bond in CD11a-I(EDTA),
between the side chains of Asp229 and Asn129, that is not
present in the CD11a-I(Mn) structure. A reason for this
difference is not clear. No nearby lattice interactions exist
in either structure that might directly influence this region
of CD11a I domain, and Asp229 and Asn129 occur on a
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Figure 2
The overall fold of the CD11a I domain. (a) Ribbon diagram of CD11a-
I(EDTA). The side chains of Ser139, Ser141, and Asp239 are shown
in green with red oxygen atoms. The N and C termini, the b strands,
and the a helical segments are labeled. (b) Stereo view of
superimposed Ca backbones of CD11a-I(EDTA) (solid blue line) and
CD11a-I(Mn) (dashed red line). The N and C termini are labeled and
every tenth residue of CD11a-I(EDTA) is indicated by a solid circle.
(Figure made with the program MOLSCRIPT [41].)
Table 4
Data collection and refinement statistics.
CD11a-I(Mn)* CD11a-I(Mg)†
Data collection statistics
Wavelength (Å) 1.54 1.54
Number of reflections 22 687 7 748
Redundancy 5.8 13.2
Completeness (%) 87.1 96.0
Signal (<|/σ|>) 20.7 19.2
Rsym (%) 10.7 12.1
Refinement and stereochemical statistics
Rvalue 0.197‡ 0.217§ 0.279# 0.292**
Rfree 0.263‡ 0.282§ 0.264# 0.278**
Average B (Å2)
for protein 11.48 11.48
for solvent 20.90 –
Rms deviations
bonds (Å) 0.009 0.009
angles (°) 1.94 1.70
B values (Å2)
bonds/angles of main chains 0.45/0.57 0.45/0.57
bonds/angles of side chains 0.80/0.94 0.78/0.94
*Data collection statistics 30.0–2.0 Å. †Data collection statistics 30.0–3.0 Å. ‡F>2σ, 6.0–2.0 Å. §All F, 6.0–2.0 Å. #F>2σ, 8.0–3.0 Å. **All F,
8.0–3.0 Å.
surface diametrically opposite to the CD11a I domain diva-
lent cation binding site.
While the differences in the metal-binding site structure
of CD11a-I(Mn) and CD11a-I(EDTA) are slight, the
absence of the bound cation results in very different
charge and surface shape in this region. Figures 4a and 4b
show the molecular surfaces of CD11a-I(Mn) and CD11a-
I(EDTA) colored by electrostatic charge and viewed to
expose the metal-binding site. Additional differences in
surface contour and charge distribution observed in these
structures arise principally from the shift in the position of
the a7 helix and rotameric shifts in solvent-exposed side
chains. The differences observed in the vicinity of the
metal-binding site result from rotameric shifts of the side
chains of Lys263, His264 and Glu269. Glu241 and His264
form a salt bridge in the CD11a-I(EDTA) structure that is
broken by a rotation of the His264 side chain in the
CD11a-I(Mn) structure. The breaking of this salt bridge
correlates with the movement of the His264-containing
b4–a6 loop (see Fig. 3) and leads to greater solvent expo-
sure of the His264 side chain. However, neither Glu241 or
His264 are conserved in all I domains and the role these
residues may play in ligand binding is unclear. The differ-
ing side-chain rotamers are likely due to the different
lattice interactions and pH (5.2 versus 8.0) of the CD11a-
I(Mn) and CD11a-I(EDTA) structures.
While the maximum distance between Ca atoms following
superposition of the CD11a-I(EDTA) and CD11a-I(Mn)
structures is ~2 Å for the N-terminal 166 of 181 modeled
residues (see Fig. 3), distances of up to 12 Å are seen
between Ca atoms in the a7 helix and C-terminal residues.
Figure 5a shows the differing courses of the a7 helix in the
CD11a I domain structures. As previously noted [16], an
unusual packing arrangement between adjacent CD11a-
I(Mn) molecules resulted in the C terminus of each mole-
cule intercalating between the a7 helix and the body of the
CD11a I domain molecule (see Fig. 5b). Examination of
the regions of the CD11a I domain that contact the a7
helix in either or both of the CD11a-I(EDTA) or CD11a-
I(Mn) structures, principally residues in the a1 helix and
b4 and b5 strands (see Fig. 1), indicates little structural
variation between these regions.
Structure of the divalent cation binding site in CD11a-
I(EDTA)
Inspection of experimental and difference electron-density
maps in the metal-binding site region of CD11a-I-(EDTA)
revealed no density either corresponding to a strong scat-
terer or separated from protein atoms by distances consis-
tent with metal coordination. Density consistent with a
weak scatterer such as a sodium ion or water molecule was,
however, present in the conserved divalent cation binding
site (see Fig. 1a). This scatterer comes within 3 Å of six
protein atoms with interatomic distances consistent with
hydrogen bond lengths. The ligands surrounding this scat-
terer do not assume a regular geometric arrangement char-
acteristic of metal coordination. Calculation of the valence
for this site by the method of Nayal and DiCera [29]
resulted in a value of 0.67. This value is inconsistent with
the scattering being due to Na+, Li+, K+, Mg2+, or Ca2+.
This density has thus been modeled as a water molecule.
One of the six ligands of this putative active site water mol-
ecule is the side chain of a lysine residue (Lys188) from an
adjacent molecule in the crystal.
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Figure 3
Differences in Ca positions following
superposition of CD11a-I(EDTA) and CD11a-
I(Mn). The higher resolution structure of the
CD11a-I(Mn) determined in the C2 space
group [16] was used for the comparison.
Regions corresponding to the positions of b
strands are colored blue, and a helical regions
are colored yellow. Residues whose side
chains interact directly with bound metal ion
or metal-bound oxygen atoms are shown in
red and labeled.
A difference in metal coordination between the CD11a
and CD11b I domain structures with bound manganese on
the one hand and the structure of the CD11b I domain
with bound magnesium, CD11b-I(Mg), on the other
results in a slightly narrower metal-binding pocket in the
CD11b-I(Mg) structure. This difference can be character-
ized by the distance between the side chain oxygen atoms
of Ser141 and Thr206 and their homologues in CD11b. In
the CD11a-I(Mn), CD11b-I(Mn) [15], and CD11b-I(Mg)
[17] structures this serine side chain directly coordinates
the metal ion, but the threonine, while directly coordinat-
ing the metal in the CD11b-I(Mg) structure, is hydrogen
bonded to a metal-coordinating water in the CD11a-I(Mn)
and CD11b-I(Mn) structures. The distance between the
side chain oxygen atoms of these serine and threonine
residues is 5.8 Å in the CD11a-I(Mn) structure while
typical magnesium coordination lengths indicate that this
distance must be ~4 Å in the CD11b-I(Mg) structure.
This distance is 4.8 Å in the CD11a-I(EDTA) structure.
Most of the difference in this distance in the CD11a-
I(EDTA) and CD11a-I(Mn) structures can be attributed
to a ~10° difference in both the φ and ψ main-chain
torsion angles of Met140. These torsion angle differences
result in a ~1.0 Å shift of Ser141 (and the following three
residues). The main-chain hydrogen bonds observed
between Ser139 and a hydrophobic loop (residues
Leu203–Leu205) in CD11a-I(Mn) are thus preserved in
the CD11a-I(EDTA) structure. 
Discussion
We have determined the crystal structure of a metal-free
form of the CD11a I domain by the MAD technique and
refined this structure with diffraction data extending to
2.0 Å Bragg spacings. We have also determined the struc-
ture of a new crystal form of the CD11a I domain with
bound manganese ion by molecular replacement and
refined this structure with data extending to 2.0 Å Bragg
spacings. The structure of the CD11a I domain with bound
manganese ion was determined in this new crystal form to
aid in the determination of a relatively low-resolution struc-
ture of the CD11a I domain with bound magnesium ion in
an isomorphous crystal lattice. Only minor rearrangement of
the metal-binding site structure is seen when the structures
of the CD11a I domain with and without bound divalent
cation are compared. Crystal structures of the CD11b I
domain with bound magnesium ion [15] and with bound
manganese ion [17] showed that the residues whose side
chains interacted directly with the metal differed in these
two structures. However, the residues interacting directly
with the metal ion in the structures of the CD11a I domain
with bound magnesium or bound manganese are the same.
Comparison of metal-free and metal-bound structures of
the CD11a I domain
Evaluating the significance of conformational differences
observed in the crystal structures of different forms of the
same molecule is not a completely objective task. Some
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Figure 4
Molecular surface representations of the CD11a I domain metal-
binding site: (a) CD11a-I(EDTA) and (b) CD11a-I(Mn). The molecules
are displayed in similar orientations and surfaces are colored by
electostatic charge with positive regions in blue and negative regions
in red. The location of the manganese ion of CD11a-I(Mn) is labeled,
and the location of the metal-binding site of CD11a-I(EDTA) is
indicated by an ‘X’. Differences in surface charge and contour
occuring at the bottom of these figures result from the shift in the a7
helix. Differences occurring just below the metal-binding site result
from the alternate side-chain positions assumed by Glu269 (on the left
of the figure) and Lys263 and His264 (on the right of the figure).
(Figures made with the program GRASP [42]). (c) Space-filling model
of CD11a-I(Mn). The residue positions at which mutations affect ligand
binding are colored in yellow [22]; the manganese ion is shown in
magenta. (Figure made with QUANTA [Polygen, Inc.].)
differences can clearly result from different crystal lattice
interactions, as has been shown by analysis of observed dif-
ferences in multiple crystal forms of the same molecule
[27,28]. Differences that result from lattice interactions are
not believed to represent induced alternative conforma-
tions, but instead appear to reflect a selection of conforma-
tions from among the low-energy states normally accessible
to the protein [27]. With the exception of a large movement
of the a7 helix, the differences in the CD11a-I(Mn) and
CD11a-I(EDTA) structures appear similar in magnitude
and nature to the differences observed in different crystal
forms of the same molecule. The movement observed in at
least the b1–a1 loop (which contains the DXSXS divalent
cation binding motif) is no doubt influenced by the pres-
ence or absence of a bound metal ion. However, this move-
ment does not alter the secondary structure of the protein,
destroy existing intraprotein interactions, create new inter-
actions, disturb buried hydrophobic residues, or appear cor-
related with the larger movements of the a7 helix. Thus,
we do not think that the differences observed in the metal-
binding site structures of CD11a-I(Mn) and CD11a-
I(EDTA) represent significantly different conformations of
the CD11a I domain other than the presence or absence of
a bound metal ion.
The absence of major differences in the structure of the
metal-binding site of the CD11a I domain with and
without bound manganese indicates that the metal is not
required to stabilize a tertiary structure similar to the previ-
ously observed structures of I domains with bound man-
ganese ion. The metal may, however, be important for
stabilizing other I domain structures, such as the ‘active’
state observed for the CD11b I domain with bound magne-
sium [15,17]. The lack of notable rearrangement of the
CD11a I domain in the absence of bound metal ion was not
necessarily expected. We had earlier noted the presence 
of a strained hydrophobic loop (encompassing leucine
residues 203, 204 and 205) stabilized by main-chain hydro-
gen bonds to the metal-coordinating loop (the DXSXS
motif) and postulated that both of these loops would be
likely to undergo significant rearrangement in the absence
of bound cation [16]. The envisioned rearrangement
clearly does not occur.
Even without large changes in the structure of the protein,
the presence or absence of a bound metal ion has dramatic
effects on the shape and electrostatic properties of the
metal-binding site (see Fig. 4a,b). If the metal-binding site
is directly involved in interactions with ligand, these
altered properties could easily underlie the cation depen-
dence of ligand binding. Several mutations that impair
interactions with ligand occur at solvent-exposed positions
near the metal-binding site of the CD11a I domain as
shown in Figure 4c. These mutations suggest that the
surface containing the metal-binding site is a contact region
for the ligand ICAM-1 [22]. Curiously, mutations at the N
terminus of the CD11a I domain on a surface diametrically
opposite the metal-binding site disrupt interactions with
ICAM-3 without affecting interactions with ICAM-1 [24].
While bound magnesium ion may be directly involved in
interactions between I domains and certain ligands, the
metal ion itself is unlikely to play a direct regulatory role
in I domain–ligand interactions. The affinities of isolated I
domains for Mg2+ are in the 10–100 micromolar range [6]
while the extracellular concentration of Mg2+ is approxi-
mately millimolar and invariant. Unless the affinity of I
domains for Mg2+ is modulated in intact integrins, the I
domain metal-binding site will be constitutively occupied
in physiological conditions.
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Figure 5
The position of the a7 helices. (a) Deviation of
the a7 helices of CD11a-I(EDTA) and
CD11a-I(Mn) following superposition. A
superposition of Ca backbone traces of
CD11a-I(EDTA) and CD11a-I(Mn) is shown.
The a7 helix of CD11a-I(EDTA) is shown in
blue, and the a7 helix of CD11a-I(Mn) is
shown in red. (b) Dimer interaction observed
in CD11a-I(Mn) and CD11a-I(Mg) crystal
structures. The structures shown constitute
the contents of one asymmetric unit. The a7
helices of each molecule are labeled. In both
figures the manganese ions are depicted as
magenta spheres. (Figures made with the
program SETOR [43].)
While the metal-binding site of the CD11a I domain
exhibits only minor changes in the presence or absence of
divalent cation, the position of the a7 helix is very differ-
ent in the CD11a-I(EDTA) and CD11a-I(Mn) structures.
The asymmetric units of all of the structures of the CD11a
I domain with bound divalent cation contain a dimer in
which the C terminus of one monomer intercalates
between the a7 helix and the body of the other monomer
and clearly influences the disposition of the a7 helix (Fig.
5b). This interaction is not seen in the metal-free struc-
ture of the CD11a I domain, and the a7 helix in this struc-
ture is considerably less well ordered with only the general
course of the helix apparent and the position of most side
chains in this region indeterminate. Following superposi-
tion of metal-free and metal-bound structures of the
CD11a I domain (Figs 2b,3) differences of up to 12 Å are
observed between the Ca positions following the first turn
of the the a7 helix.
Large changes in the position of the a7 helix are observed
between structures of the CD11b I domain with either
manganese or magnesium bound [17]. While similar in
magnitude, these changes differ in nature from the
changes observed in the CD11a I domain structures and
also involve the b strand and loop preceding the a7 helix.
The shift in the position of the a7 helix in the CD11a I
domain structures is principally confined to regions follow-
ing the first turn of the helix. The change in the position
of the a7 helix in the CD11b structures appears correlated
with changes in metal-binding site structure and exposure
of two key hydrophobic residues, Phe275 and Phe302; it
has been suggested that these changes represent a transi-
tion from low- to high-affinity forms of the CD11b I
domain. The homologous phenylalanine residues of the
CD11a I domain do not shift significantly and remain
buried in both the metal-free and metal-bound structures.
This observation indicates the a7 helix to be a labile struc-
ture in isolated I domains independent of correlated
movements in the metal-binding site. The free energies of
‘active’ and ‘inactive’ forms of I domains are likely to be
similar [17,30], and it will be interesting to see the I
domain conformation with bound ligand if such co-crystals
can be obtained.
Metal coordination
Manganese and magnesium ions show differences in both
their affinity for I domains and their ability to stimulate
high-affinity ligand binding. Manganese typically has a
higher affinity for I domains and is able to stimulate high-
affinity ligand binding in integrins independent of other
stimuli [4,6]. The same or homologous amino acid side
chains interact directly with the bound metal or metal-
bound water molecules and form an octahedral coordina-
tion sphere in all I domain structures. However, the nature
of the interactions of specific side chains differs in the
structure of the CD11b-I(Mg) when compared to the
CD11a-I(Mn) and CD11b-I(Mn) structures. In the struc-
ture of CD11b-I(Mg) Thr209 directly coordinates the
magnesium ion while Asp242 hydrogen bonds to a metal
bound water molecule. In the structures of CD11a-I(Mn)
and CD11b-I(Mn) Thr209 (Thr206 in CD11a) hydrogen
bonds to a metal-bound water while Asp242 (homologous
to Asp239 in CD11a) directly coordinates the manganese
ion. A direct interaction that occurs between a glutamic
acid side chain from an adjacent molecule in the crystal
lattice and the magnesium ion in the CD11b-I(Mg) struc-
ture is not present in the I domain structures with bound
manganese. The presence of the same type of metal coor-
dination in the structure of CD11a-I(Mg), as seen in the
earlier I domain structures with bound manganese, indi-
cates that the differences in coordination in the CD11b
structures are not a consequence of whether magnesium
or manganese is bound. As also noted by Lee et al. [17], it
is thus likely that the differences in metal coordination are
principally due to the participation of the bound magne-
sium in the CD11b I domain structure in a crystal lattice
interaction.
While structures of isolated I domains in various contexts
provide valuable insight into integrin function, many ques-
tions remain. Regions outside of the I domain have also
been implicated in the interactions of I domain-containing
integrins with ligands [20,31], and the role or roles played
by these regions and their relationship to the I domain is
poorly understood. The b chains of I domain containing
integrins also contain a divalent cation binding motif, that is
probably embedded in an I domain like structure, and is
essential for ligand binding. The specific roles played by
each metal-binding site in ligand binding need to be under-
stood. The possibility also exists that dramatic changes in I
domain tertiary structure may not underlie different affinity
states. Changes in integrin quaternary structure or inter-
actions with other molecules may also influence integrin
affinity for ligand.
Biological implications
The affinity of many integrins for ligand may be increased
in response to appropriate cellular stimuli by a mecha-
nism that is believed to involve a conformational change
in the integrin. High affinity interactions between
members of the integrin family of receptors and their
ligands are typically dependent on the presence of divalent
cations. The a subunits of a subset of integrins contain an
inserted or ‘I’ domain ~200 amino acids in length that
appears to play a significant role in ligand interactions. It
has been proposed that the cation dependence of integrin
interactions results from either the stabilization of an
active structure by the metal ion, or the direct participa-
tion of the bound metal ion in interactions with the ligand.
Earlier structures of I domains from CD11a (with bound
manganese) and CD11b (with bound magnesium and
manganese) have identified a conserved metal-binding
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site. In the case of CD11b, the structures revealed a con-
formational change between manganese- and magne-
sium-bound forms of the I domain that has been proposed
to reflect high- and low-affinity states of the I domain.
We report here crystal structures of the CD11a I
domain in the absence of bound metal ion and in the
presence of bound magnesium ion. No large differences
are observed in the structures of the metal-binding site
of the CD11a I domain with and without bound man-
ganese ion. The cation dependence of ligand binding is
thus not likely to be due to stabilization of a structure
similar to the I domain structures with bound man-
ganese. Unlike the case for the CD11b I domain, no dif-
ferences in the residues whose side chains directly
coordinate the metal ion are observed between man-
ganese- and magnesium-bound structures of the CD11a
I domain, indicating that any differences in metal coor-
dination are not dependent on the specific cation bound
to the I domain. As in the case of the CD11b I domain
structures, a significant shift in the position of an
a helix, a7, is observed in different crystal forms of the
CD11a I domain. These shifts are not, however, corre-
lated with changes in the metal-binding site.
Materials and methods
Expression and purification of the CD11a I domain
The CD11a I-domain was expressed as described previously [16].
Briefly, a region of the CD11a gene encoding residues Cys125 to
Gly311 was subcloned into the pET11c expression vector (Novagen)
and transformed into E. coli strains BL21(DE3) and 834(DE3) [32].
Protein expression was induced in log phase growth cells by addition
of isopropyl-b-D-thiogalactopyranoside (IPTG) and cells were har-
vested 3–4 h after induction. Following lysis of the cells by sonication,
most of the CD11a I domain protein was found in the insoluble fraction
of the lysate. This fraction was resolubilized in 7M urea, 10 mM Tris pH
7.5, 40 mM b-mercaptoethanol (b-ME), and either 5 mM MnCl2, 5 mM
MgCl2, or 5 mM ethylenediaminetetraacetic acid (EDTA) and dialyzed
in successive steps over 2 days into 10 mM Tris pH 7.5, 5 mM b-ME,
and either 5 mM MnCl2, 5 mM MgCl2, or 2 mM EDTA. A precipitate
was removed by centrifugation, and the supernatant was concentrated
and loaded on to a Mono Q column (Pharmacia). In all cases the
CD11a I domain protein passed through the column and was esti-
mated to be greater than 98% pure by polyacrylamide gel elec-
trophoresis. The CD11a I domain protein was concentrated and
dialyzed into 5 mM b-ME, and either 5 mM MnCl2, 5 mM MgCl2, or
2 mM EDTA. Selenomethionyl-substituted protein was prepared by
using the methionine-auxotrophic strain 834(DE3) as described [33]
and was purified in the same manner as native protein.
Crystallization of the CD11a I domain
All crystals were grown from hanging drops by the method of vapor 
diffusion. Mn2+-bound, Mg2+-bound, and metal-free forms of CD11a I
domain crystals were prepared with protein refolded and dialyzed in the
presence of the appropriate cation or EDTA. Diffraction-quality crystals
of metal-free SeMet CD11a I domain protein were only obtained when
the crystallization trials were carried out with degassed buffers in an
anaerobic chamber. Microseeding proved useful for all forms of both
native and SeMet protein crystals.
Crystallization of the CD11a I domain with bound Mn2+
Crystals of the CD11a I domain with bound Mn2+ ion were grown by
mixing 1 ml of a 15 mgml–1 solution of CD11a I domain protein in 5 mM
MnCl2, 5 mM b-ME with 1ml of a reservoir solution of 14–20% PEG
3350, 100 mM MnCl2, 50 mM sodium acetate, pH 5.2 and equilibrating
the mixture over the reservoir solution as described previously [16]. Crys-
tals grew to a typical size of 0.2×0.1×0.1 mm in 3–7 days. Most Mn2+
crystals are in space group C2 with unit cell dimensions a=131.13 Å,
b=45.45 Å, c=66.13 Å, and b=99.8°, but some Mn2+ crystals are in
space group P21212 with unit cell dimensions a=76.16 Å, b=78.63 Å,
and c=66.37 Å. The asymmetric unit of both of these crystal forms con-
tains two molecules.
Crystallization of the CD11a I domain with bound Mg2+
Crystals of the CD11a I domain with bound Mg2+ ion were grown by
mixing 1 ml of a 15 mgml–1 solution of CD11a I domain protein in 5
mM MgCl2, 5 mM b-ME with 1 ml of a reservoir solution of 14–20%
PEG 3350, 100 mM MgCl2, 50 mM sodium acetate, pH 5.2 and
equilibrating the mixture over the reservoir solution. Crystals grew to
~0.03 × 0.03 × 0.2 mm over 3–7 days and are in space group P21212
with unit cell dimensions a = 75.56 Å, b = 78.32 Å, and c = 66.28 Å
with two molecules in the asymmetric unit.
Crystallization of metal-free CD11a I domain
Crystals of metal-free CD11a I domain were grown by mixing 1 ml of a
10–20 mgml–1 solution of CD11a I domain protein in 2 mM EDTA, 5
mM b-ME with 1 ml of a reservoir solution of 30–33% PEG 3350, 1
mM EDTA, 30 mM Tris pH 8.0, 2 mM b-ME and equilibrating the
mixture over the reservoir solution. Crystals grew to a final size of
0.04 ×0.03 ×0.2 mm over 3–7 days and are in space group P212121
with unit cell dimensions a = 63.09 Å, b = 63.69 Å, and c = 40.19 Å.
Data collection and processing
All data were collected from crystals soaked for at least 15 minutes in
reservoir buffer containing 10% w/v ethylene glycol and flash frozen in
a gaseous nitrogen stream at –180°C. Native data from Mg2+, Mn2+,
and metal-free crystal forms of the CD11a I domain were collected with
an R-axis IIc detector and CuKa radiation from a Rigaku RU200 rotating
anode. MAD data from SeMet metal-free CD11a I domain crystals were
collected at four wavelengths 0.9879,0.9793, 0.9791 and 0.9686 Å
(Table 2) at beamline X-4A of the National Synchrotron Light Source at
Brookhaven National Laboratory using phosphor-imaging plates as
detectors. Oscillations of 2.5° per image with no overlap were collected
at φ and φ+180° for each wavelength.
All diffraction images were processed using the program DENZO and
scaled with the program SCALEPACK [34]. < I+> and < I–> were used
for MAD phase determination and partially recorded reflections were
used in all cases. Diffraction data from different wavelengths were scaled
with WVLSCL, and FAs and optimal f′ and f′′ were calculated with
MADLSQ [35].
Determination of the structure of the metal-free CD11a I
domain
The structure of the metal-free form of the CD11a I domain was deter-
mined by the MAD technique with SeMet protein [36]. Four selenium
sites were deduced from inspection of FA Patterson and difference
Fourier maps. Phase determinations were performed with the program
MLPHARE [37], and solvent-flattening and histogram matching were
performed with the program DM [38]. The initial electron-density maps
calculated at 3.0 Å resolution allowed unambiguous positioning of the
Mn2+ structure within these maps, this structure was used as a guide
when building the metal-free structure. Residues from Gly128 to
Phe292, corresponding to all of the I domain except the a7 helix, could
be confidently placed in the initial electron-density maps. Clear helical
density existed for residues beyond Phe292, but this density was rela-
tively poorly defined and precluded precise placement of side chains.
Several rounds of simulated annealing and/or Powell minimization with
the program X-PLOR [39] alternated with model building with the
program O [40] resulted in the current model consisting of residues
Gly128 to Val308 (1458 nonhydrogen protein atoms) and 110 water
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molecules. Refinement statistics and stereochemical parameters for
this model are shown in Tables 1 and 3.
Determination of the structure of the Mn2+-bound form of the
CD11a I domain
The structure of the Mn2+-bound form of the CD11a I domain in space
group P21212 was solved by molecular replacement using the structure
of the Mn2+-bound form of this domain solved in the space group C2
[16] as the search model. Rotation and translation functions were per-
formed with the program X-PLOR and resulted in unambiguous solu-
tions for two independent molecules in the asymmetric unit. Successive
rounds of Powell minimization with X-PLOR alternated with model
building with the program O resulted in the current model consisting of
residues Gly128 to Glu310 for each molecule in the asymmetric unit
(2950 total protein atoms), two manganese, two chloride ions, and 247
water molecules. Refinement statistics and stereochemical parameters
for this model are shown in Table 4.
Determination of the structure of the Mg2+-bound form of the
CD11a I domain
The structure of the Mg2+-bound form of the CD11a I domain was
determined by rigid-body refinement of the structure of the Mn2+-bound
structure determined in the P21212 space group. Prior to the rigid-body
refinement the Mn2+-bound structure was subjected to two independent
simulated annealing refinements starting at 800 K. Atoms within 8 Å of
the manganese ion bound to one of the I domains in the asymmetric unit
were omitted from one refinement, and atoms within 8 Å of the man-
ganese ion bound to the other I domain in the asymmetric unit were
omitted from the second refinement. The results of both of these simu-
lated annealings were used in rigid-body refinements versus the diffrac-
tion data from the Mg2+-containing crystals. Electron-density maps were
calculated from each refinement with (2Fo–Fc) coefficients from which
atoms within an 8 Å sphere around the corresponding manganese ion
were omitted from the map calculation. Inspection of these maps
resulted in minor adjustments to the side chains of nine amino acids, but
no further refinement was undertaken. The rebuilt model was used to
recalculate the omit maps and inspect the metal-coordination. Refine-
ment statistics and stereochemical parameters are shown in Table 4.
Accession numbers
Atomic coordinates and structure factors have been deposited in the
Brookhaven Protein Data Bank: CD11a I domain without bound cation
PDB ID code 1ZON, and for related structure factors R1ZONSF;
CD11a-I(Mg) PDB ID code 1ZOO, and for related structure factors
R1ZOOSF; Cd11a-I(Mn) PDB ID code 1ZOP, and for related structure
factors R1ZOPSF.
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